Magnus Financial Group’s Alaunos Therapeutics TCRT Stock Holding History

Magnus Financial Group’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-73	Closed	-$6.93K	–	287
2023 Q1	$6.93K	Hold	73	–	–	﹤0.01%	275
2022 Q4	$7.14K	Hold	73	–	–	﹤0.01%	265
2022 Q3	$19K	Hold	73	–	–	﹤0.01%	251
2022 Q2	$14K	Hold	73	–	–	﹤0.01%	272
2022 Q1	$7K	Buy	+73	New	+$9.37K	﹤0.01%	293
2021 Q1	–	Sell	-67	Closed	-$25K	–	348
2020 Q4	$25K	Hold	67	–	–	﹤0.01%	353
2020 Q3	$25K	Hold	67	–	–	﹤0.01%	311
2020 Q2	$33K	Hold	67	–	–	﹤0.01%	678
2020 Q1	$25K	Hold	67	–	–	﹤0.01%	558
2019 Q4	$47K	Hold	67	–	–	0.01%	588
2019 Q3	$43K	Hold	67	–	–	0.01%	532
2019 Q2	$58K	Hold	67	–	–	0.01%	532
2019 Q1	$39K	Buy	+67	New	+$28K	0.01%	512

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnus Financial Group's TCRT Position: Q2 2023 in Review

Magnus Financial Group sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 73 shares — an estimated $6.93K sold.

Magnus Financial Group first reported a position in TCRT in Q1 2019 and held it in 13 quarters. The position peaked at $58K in Q2 2019. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

Magnus Financial Group reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
Magnus Financial Group sold 73 Alaunos Therapeutics shares in Q2 2023, an estimated $6.93K.
Magnus Financial Group first reported a position in Alaunos Therapeutics in Q1 2019 and held it in 13 quarters.
Magnus Financial Group's Alaunos Therapeutics position peaked at $58K in Q2 2019.
100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on Magnus Financial Group's 13F filing for Q2 2023, filed 19 Jul 2023.